A Review of Novel Medical Treatments for Thyroid Eye Disease

키워드

참고문헌 (83)

1. Chin YH, "Prevalence of thyroid eye disease in Graves’ disease : a meta-analysis and systematic review", Clin Endocrinol(Oxf), 93, pp.363~374 (2020)
2. Hoang TD, "2022 Update on clinical management of Graves disease and thyroid eye disease", Endocrinol Metab Clin North Am, 51, pp.287~304 (2022)
3. Smith TJ, "Graves’ Disease", N Engl J Med, 375, pp.1552~1565 (2016)
4. Bartalena L, "Thyroid eye disease: epidemiology, natural history, and risk factors", Ophthalmic Plast Reconstr Surg, 39(6S), pp.S2~S8 (2023)
5. Woo KI, "Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients", Korean J Ophthalmol, 27, pp.397~404 (2013)
6. Sikder S, "Thyroid eye disease : pathogenesis and treatment", Ophthalmologica, 224, pp.199~203 (2010)
7. Khong JJ, "Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research(ATOR)study", J Clin Endocrinol Metab, 101, pp.2711~2720 (2016)
8. Weiler DL, "Thyroid eye disease : a review", Clin Exp Optom, 100, pp.20~25 (2017)
9. Bartley GB, "The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota", Trans Am Ophthalmol Soc, 92, pp.477~588 (1994)
10. Mourits MP, "Clinical criteria for the assessment of disease activity in Graves’ophthalmopathy : a novel approach", Br J Ophthalmol, 73, pp.639~644 (1989)
11. Bartalena L, "The 2021 European Group on Graves’ Orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves’orbitopathy", Eur J Endocrinol, 185, pp.G43~G67 (2021)
12. Tanda ML, "Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center", J Clin Endocrinol Metab, 98, pp.1443~1449 (2013)
13. Pritchard J, "Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway", J Immunol, 170, pp.6348~6354 (2003)
14. Tsui S, "Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors : a tale of two antigens implicated in Graves’ disease", J Immunol, 181, pp.4397~4405 (2008)
15. Shan SJ, "The pathophysiology of thyroid eye disease", J Neuroophthalmol, 34, pp.177~185 (2014)
16. Yoon JS, "Thyroid eye disease : from pathogenesis to targeted therapies", Taiwan J Ophthalmol, 12, pp.3~11 (2022)
17. Bartalena L, "Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy", Front Endocrinol(Lausanne), 11, pp.615993~ (2020)
18. Bartalena L, "Prevention of Graves’ ophthalmopathy", Best Pract Res Clin Endocrinol Metab, 26, pp.371~379 (2012)
19. Perros P, "A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy", J Clin Endocrinol Metab, 90, pp.5321~5323 (2005)
20. Burch HB, "Management of Graves disease : a review", JAMA, 314, pp.2544~2554 (2015)
21. Vannucchi G, "Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis", J Clin Endocrinol Metab, 94, pp.3381~3386 (2009)
22. Kim TH, "Serum selenium levels in patients with Graves disease : associations with clinical activity and severity in a retrospective case-control study", Korean J Ophthalmol, 36, pp.36~43 (2022)
23. Marcocci C, "Selenium and the course of mild Graves’ orbitopathy", N Engl J Med, 364, pp.1920~1931 (2011)
24. Kim BY, "Anti-inflammatory and antioxidant effects of selenium on orbital fibroblasts of patients with Graves ophthalmopathy", Ophthalmic Plast Reconstr Surg, 37, pp.476~481 (2021)
25. Kahaly GJ, "Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy", J Clin Endocrinol Metab, 90, pp.5234~5240 (2005)
26. Zang S, "Clinical review : intravenous glucocorticoids for Graves’ orbitopathy : efficacy and morbidity", J Clin Endocrinol Metab, 96, pp.320~332 (2011)
27. Bartalena L, "Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy", J Clin Endocrinol Metab, 97, pp.4454~4463 (2012)
28. Marino M, "Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy", Thyroid, 14, pp.403~406 (2004)
29. Langericht J, "Glucocorticoids in Graves’ orbitopathy : mechanisms of action and clinical applicat ion", Ther Adv Endocrinol Metab, 11, pp.2042018820958335~ (2020)
30. Campi I, "Therapy of endocrine disease : endocrine dilemma : management of Graves’ orbitopathy", Eur J Endocrinol, 175, pp.R117~R133 (2016)
31. Tanda ML, "Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy", J Clin Endocrinol Metab, 97, pp.3857~3865 (2012)
32. Kahaly GJ, "Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial", J Clin Endocrinol Metab, 85, pp.102~108 (2000)
33. Prummel MF, "A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy", J Clin Endocrinol Metab, 89, pp.15~20 (2004)
34. Mourits MP, "Radiotherapy for Graves’ orbitopathy : randomised placebo-controlled study", Lancet, 355, pp.1505~1509 (2000)
35. Bradley EA, "Orbital radiation for graves ophthalmopathy : a report by the American Academy of Ophthalmology", Ophthalmology, 115, pp.398~409 (2008)
36. Marcocci C, "Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone : results of a prospective randomized study", J Endocrinol Invest, 14, pp.853~860 (1991)
37. Wakelkamp IM, "Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study", Ophthalmology, 111, pp.1557~1562 (2004)
38. Kim JW, "Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy", Graefes Arch Clin Exp Ophthalmol, 254, pp.991~998 (2016)
39. Azzola A, "Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation", Transplantation, 77, pp.275~280 (2004)
40. Kahaly GJ, "Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial", Lancet Diabetes Endocrinol, 6, pp.287~298 (2018)
41. Feng W, "Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves’ orbitopathy : a meta-analysis", Bioengineered, 13, pp.14719~14729 (2022)
42. Kahaly G, "Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy:a controlled, randomized and prospective study", Eur J Clin Invest, 16, pp.415~422 (1986)
43. Prummel MF, "Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy", N Engl J Med, 321, pp.1353~1359 (1989)
44. Smith TJ, "Teprotumumab for thyroid-associated ophthalmopathy", N Engl J Med, 376, pp.1748~1761 (2017)
45. Douglas RS, "Teprotumumab for the treatment of active thyroid eye disease", N Engl J Med, 382, pp.341~352 (2020)
46. Jain AP, "Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease", Br J Ophthalmol, 106, pp.165~171 (2022)
47. Kossler AL, "Teprotumumab and the evolving therapeutic landscape in thyroid eye disease", J Clin Endocrinol Metab, 107(Suppl_1), pp.S36~S46 (2022)
48. Sears CM, "Hearing dysfunction after treatment with teprotumumab for thyroid eye disease", Am J Ophthalmol, 240, pp.1~13 (2022)
49. Douglas RS, "Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study", Ophthalmology, 129, pp.438~449 (2022)
50. Ugradar S, "Teprotumumab for the treatment of chronic thyroid eye disease", Eye(Lond), 36, pp.1553~1559 (2022)
51. Diniz SB, "Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population", Ophthalmic Plast Reconstr Surg, 37, pp.583~591 (2021)
52. Mulvihill MJ, "Discovery of OSI-906 : a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor", Future Med Chem, 1, pp.1153~1171 (2009)
53. Gulbins A, "Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease", Front Endocrinol(Lausanne), 14, pp.1211473~ (2023)
54. Dickinson B, "VRDN-002, a second-generation insulin like growth factor-1 receptor (IGF-1R) inhibitory antibody for thyroid eye disease: preclinical pharmacokinetics and clinical promise", Invest Ophthalmol Vis Sci, 63, pp.3995-A0337~ (2022)
55. Salvi M, "Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy : a randomized controlled study", J Clin Endocrinol Metab, 100, pp.422~431 (2015)
56. Chen J, "Intravenous rituximab therapy for active Graves’ ophthalmopathy : a meta-analysis", Hormones(Athens), 20, pp.279~286 (2021)
57. Stan MN, "Randomized controlled trial of rituximab in patients with Graves’orbitopathy", J Clin Endocrinol Metab, 100, pp.432~441 (2015)
58. Stan MN, "Management of endocrine disease : rituximab therapy for Graves’ orbitopathy : lessons from randomized control trials", Eur J Endocrinol, 176, pp.R101~R109 (2017)
59. Deltour JB, "Efficacy of rituximab in patients with Graves’ orbitopathy : a retrospective multicenter nationwide study", Graefes Arch Clin Exp Ophthalmol, 258, pp.2013~2021 (2020)
60. Perez-Moreiras JV, "Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy : a randomized clinical trial", Am J Ophthalmol, 195, pp.181~190 (2018)
61. Silkiss RZ, "Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab", Can J Ophthalmol, 56, pp.66~70 (2021)
62. Molina-Molina M, "Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells", BMC Pulm Med, 18, pp.63~ (2018)
63. Zhang L, "Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves’ orbitopathy", J Clin Endocrinol Metab, 97, pp.653~662 (2012)
64. Krassas GE, "Thyroid-associated ophthalmopathy in juvenile Graves’ disease: clinical, endocrine and therapeutic aspects", J Pediatr Endocrinol Metab, 19, pp.1193~1206 (2006)
65. Sehgal SN, "Sirolimus: its discovery, biological properties, and mechanism of action", Transplant Proc, 35(3 Suppl), pp.7S~14S (2003)
66. Roos JC, "Sirolimus(rapamycin)for the targeted treatment of the fibrotic sequelae of Graves’ orbitopathy", Eye(Lond), 33, pp.679~682 (2019)
67. Lanzolla G, "Sirolimus as a second-line treatment for Graves’ orbitopathy", J Endocrinol Invest, 45, pp.2171~2180 (2022)
68. van Klei WA, "Anti-inflammatory effects of perioperative statin therapy", Can J Anaesth, 59, pp.516~521 (2012)
69. Lambert EM, "Statins: cause of fibrosis or the opposite? Effect of cardiovascular drugs in idiopathic pulmonary fibrosis", Respir Med, 176, pp.106259~ (2021)
70. Jougasaki M, "Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase", signal transducers and activators of transcription pathways in human vascular endothelial cells, 2010, pp.159, 1294~1303
71. Ferreira GA, "Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus", Clin Exp Rheumatol, 34, pp.42~48 (2016)
72. Lanzolla G, "Relationship between serum cholesterol and Graves’ orbitopathy(GO) : a confirmatory study", J Endocrinol Invest, 41, pp.1417~1423 (2018)
73. Marino M, "Statins: a new hope on the horizon of Graves orbitopathy?", J Clin Endocrinol Metab, 106, pp.e2819~e2821 (2021)
74. Nilsson A, "Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease", J Clin Endocrinol Metab, 106, pp.1325~1332 (2021)
75. Reynolds AL, "The effect of oral statin therapy on strabismus in patients with thyroid eye disease", J AAPOS, 22, pp.340~343 (2018)
76. Lanzolla G, "Statins for Graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial", Lancet Diabetes Endocrinol, 9, pp.733~742 (2021)
77. Malboosbaf R, "Statins and thyroid eye disease (TED): a systematic review", Endocrine (2024)[DOI]
78. Peter HH, "Targeting FcRn for immunomodulation: benefits, risks, and practical considerations", J Allergy Clin Immunol, 146, pp.479~491 (2020)
79. Janes J, "ODP509 proof-ofconcept, multicenter, open-label phase 2a study of batoclimab in active and moderate-to-severe thyroid eye disease", J Endocr Soc, 6(Supplement_1), pp.A778~A779 (2022)
80. Furmaniak J, "In vivo effects of a human thyroid-stimulating monoclonal autoantibody(M22)and a human thyroid-blocking autoantibody(K1-70)", Auto Immun Highlights, 3, pp.19~25 (2011)
81. Ryder M, "Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves’ disease, and Graves’ophthalmopathy", Thyroid, 31, pp.1597~1602 (2021)
82. Furmaniak J, "TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves’ disease and Graves’orbitopathy : results from a phase I clinical trial", Clin Endocrinol(Oxf), 96, pp.878~887 (2022)
83. Krause G, "Intervention strategies into glycoprotein hormone receptors for modulating (Mal-)function, with special emphasis on the TSH receptor", Horm Metab Res, 50, pp.894~907 (2018)

관련 논문AI추천